{"text_format":"dbase-jsonl-2026-09-30","columns":[{"name":"C_DOCTOR","type":"number","width":5,"decimals":0},{"name":"FIO","type":"character","width":30},{"name":"Q","type":"character","width":2},{"name":"TIP","type":"character","width":1},{"name":"OTD","type":"character","width":4},{"name":"COD","type":"number","width":6,"decimals":0},{"name":"K_G","type":"number","width":5,"decimals":0},{"name":"K_U","type":"number","width":6,"decimals":0},{"name":"DS","type":"character","width":6},{"name":"K_DN","type":"number","width":6,"decimals":0},{"name":"NAME_USL","type":"character","width":100},{"name":"P_CENA","type":"number","width":11,"decimals":2},{"name":"CENA_USL","type":"number","width":11,"decimals":2},{"name":"PR_ALL","type":"number","width":11,"decimals":2},{"name":"KEYFIELD","type":"character","width":5},{"name":"N_PEOP","type":"number","width":6,"decimals":0},{"name":"VR_UET","type":"number","width":10,"decimals":2},{"name":"MS_UET","type":"number","width":10,"decimals":2},{"name":"MASK","type":"number","width":1,"decimals":0}],"n_rows":14,"rows_kept":14,"cut":false,"deleted_skipped":0,"read_ended":"whole","bounds":"16MiB/16384/4096/first_that_fit","version":"dbase_level_three","encoding_class":"enc_absent","reader":"statdb_count/12"}
[17,"ПОЛЯКОВА АЛЛА МАРКОВНА",null,null,"0001",1602,null,9,null,null,"Консультация (консилиум) специалиста, к.м.н. в поликлинике",null,13.43,120.87,"17",126,27.00,0.00,1]
[17,"ПОЛЯКОВА АЛЛА МАРКОВНА",null,null,"0001",25026,null,9,null,null,"Подсчет тромбоцитов фазово-контрастным методом",null,15.00,135.00,"17",126,22.50,0.00,1]
[17,"ПОЛЯКОВА АЛЛА МАРКОВНА",null,null,"0001",26032,null,9,null,null,"Определение фибриногена в плазме крови методом ИФА",null,9.22,82.98,"17",126,4.05,1.35,1]
[17,"ПОЛЯКОВА АЛЛА МАРКОВНА",null,null,"0001",26033,null,9,null,null,"Определение  фибринолитической  активности плазмы (время лизиса эуглобулинов плазмы)",null,6.61,59.49,"17",126,9.90,0.00,1]
[17,"ПОЛЯКОВА АЛЛА МАРКОВНА",null,null,"0001",26056,null,9,null,null,"Определение протромбинового (тромбопластинового) времени с тромбопластинкальциевой  смесью",null,1.16,10.44,"17",126,0.45,1.80,1]
[17,"ПОЛЯКОВА АЛЛА МАРКОВНА",null,null,"0001",26061,null,9,null,null,"Обработка  венозной крови, включая регистрацию (получ. плазмы и сывор. крови)",null,1.58,14.22,"17",126,0.45,2.70,1]
[17,"ПОЛЯКОВА АЛЛА МАРКОВНА",null,null,"0001",26062,null,9,null,null,"Опр.активированного  времени рекальцификации плазмы с суспензией каолина",null,5.51,49.59,"17",126,0.45,10.80,1]
[17,"ПОЛЯКОВА АЛЛА МАРКОВНА",null,null,"0001",26065,null,9,null,null,"Проба на ингибицию по активтрованному частичному тромбопластиновому времени ( АЧТВ)  эритрофосфатидк",null,12.01,108.09,"17",126,18.00,0.00,1]
[17,"ПОЛЯКОВА АЛЛА МАРКОВНА",null,null,"0001",26066,null,9,null,null,"Определение  тромбинового времени со стандартным количеством тромбина (ТВ)",null,3.03,27.27,"17",126,4.50,0.00,1]
[17,"ПОЛЯКОВА АЛЛА МАРКОВНА",null,null,"0001",26186,null,9,null,null,"Аггрегация тромбоцитов, стимулированная АДФ",null,8.23,74.07,"17",126,9.00,4.50,1]
[17,"ПОЛЯКОВА АЛЛА МАРКОВНА",null,null,"0001",26187,null,9,null,null,"Аггрегация тромбоцитов, стимулированная адреналином",null,8.23,74.07,"17",126,9.00,4.50,1]
[17,"ПОЛЯКОВА АЛЛА МАРКОВНА",null,null,"0001",26188,null,9,null,null,"Аггрегация тромбоцитов, стимулированная коллагеном",null,8.23,74.07,"17",126,9.00,4.50,1]
[17,"ПОЛЯКОВА АЛЛА МАРКОВНА",null,null,"0001",26189,null,9,null,null,"Аггрегация тромбоцитов, стимулированная ристомицином",null,8.23,74.07,"17",126,9.00,4.50,1]
[17,"ПОЛЯКОВА АЛЛА МАРКОВНА",null,null,"0001",26193,null,9,null,null,"Электрокоагулография",null,7.36,66.24,"17",126,9.00,2.70,1]